Speech-Language Pathologists in Casey, IL Accepting Medicare

4 Speech-Language Pathologists found. Showing 1 - 4

Mrs. Lyn Michele Cochonour Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 301 E Monroe Ave, Casey, IL 62420 Phone: 217-932-2178

Sarah Elizabeth Pfleging Vester, M.S.,CCC-SLP/L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10990 N Coles St, Casey, IL 62420 Phone: 217-508-9870

Jeanne Ann Unzicker Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 301 E Monroe Ave, Casey, IL 62420 Phone: 217-932-3869

Makenzie Alicen Goble, M.S. CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 100 Ne 15th St, Casey, IL 62420 Phone: 217-932-5217

News Archive

Study demonstrates significance of EMT as potential therapeutic target for reversing kidney disease

Adults who are worried or terrified sometimes curl up into a fetal position. Likewise, adult cells that are injured, including genetic injury leading to cancer, initiate a process that was present during embryonic development.

UCI study improves understanding of brain's navigational system

The ability to successfully navigate in the environment is essential both for animals searching for food or escaping predators, as well as for human urban dwellers. It is something we take for granted, but under the hood, it is supported by still incompletely understood brain networks that continuously calculate our position in the environment.

Asymptomatic individuals the biggest problem in COVID battle

The researchers noted in a study published in the journal Science, that asymptomatic cases are those that do not manifest symptoms for the infection duration. In contrast, presymptomatic cases develop symptoms later in the course of infection.

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in an investigator sponsored Phase I/IIa clinical study of AR-42 (formerly OSU-HDAC42) at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) in adult patients with relapsed or refractory multiple myeloma (MM), chronic lymphocytic leukemia (CLL) or lymphoma.

Read more Medical News

› Verified 8 days ago